联合转染Livin和Survivin shRNA表达载体对肝癌HepG2细胞生物学行为的影响

目的:分别构建Livin、Survivin基因短发夹RNA(shRNA)真核表达载体,探究联合转染Livin和Survivin真核表达载体对肝癌HepG2细胞生物学行为的影响。方法:分别设计并构建针对Livin、Sur-vivin基因shRNA真核表达载体pSD11-Livin和pSD11-Survivin,脂质体法单独或联合转染肝癌HepG2细胞,分空白对照组、质粒对照组、Survivin组、Livin组和共转染组。荧光定量PCR、Western blot分别检测Livin、Survivin mRNA及蛋白的相对表达量,MTT法检测细胞增殖的变化,TUNEL法检测细胞凋亡率。结果:针对Livin、Survivin基因的shRNA真核表达载体构建成功。共转染组Livin、SurvivinmRNA相对表达量分别为0.120±0.022、0.325±0.125,与单独转染组相比显著降低(P<0.05);共转染组Livin、Survivin蛋白相对表达量分别为0.412±0.099、0.473±0.051,与单独转染组相比差异具有统计学意义(P<0.05)。共转染组转染后48、60、72 h细胞生长抑制率均显著高于单独转染组(P<0.05),转染后48 h细胞凋亡率明显上升(P<0.05)。结论:针对Livin、Survivin基因的shRNA真核表达载体构建成功。联合转染pSD11-Livin和pSD11-Survivin更有效地降低了Livin和Survivin基因在HepG2细胞中的表达,更显著地抑制了肝癌细胞的增殖,促进了肝癌细胞的凋亡。     

携Jagged 2基因siRNA慢病毒表达载体的构建及其转染对胰腺癌细胞影响

目的:构建携带Jagged 2(JAG2)基因siRNA的慢病毒表达载体,并观察其转染人胰腺癌细胞生物学特性的影响。方法:采用基因重组技术构建若干携JAG2基因siRNA片段的慢病毒表达载体,将其转染经酶解法从胰腺癌组织标本中原代分离的胰腺癌细胞;选择对JAG2基因抑制效率最高的siRNA片段,通过MTT法、流式细胞术、Transwell小室实验观察其转染对原代胰腺癌细胞生长、凋亡、细胞周期及侵袭转移能力的影响。结果:所构建的携JAG2基因siRNA片段的慢病毒表达载体均能不同程度降低原代胰腺癌细胞JAG2 mRNA与蛋白的表达。JAG2 siRNA转染后,胰腺癌细胞的增殖明显降低、凋亡与S期阻滞明显增强、侵袭转移能力明显减弱(均P0.05)。结论:成功构建携JAG2基因siRNA慢病毒表达载体,其转染能有效削弱人胰腺癌细胞的恶性生物学特征。     

运用siRNA建立稳定低表达IGF1R基因的肝癌细胞株的实验研究

目的运用siRNA技术在肝癌细胞株中建立稳定低表达人胰岛素样生长因子1类受体(IGF1R)基因的细胞株。方法构建包含封闭IGF1R基因的真核表达载体pSUPER-IGF1R-siRNA,转染SMMC7721和Hep3B细胞,G418筛选表达稳定的细胞株。通过RT-PCR、Western-blot分析与鉴定IGF1R mRNA和蛋白及cyclin D1、cyclinB1蛋白的表达,并绘制细胞生长曲线。结果在SMMC7721和Hep3B细胞中成功建立低表达IGF1R基因的细胞株,其生长明显减慢(P<0.05),且其cyclinD1表达亦明显下降(P<0.05)。结论pSUPER-IGF1R-siRNA能抑制SMMC7721和Hep3B细胞的生长。     

单基因人肝癌耐药细胞株(HepG2/MRP1)的构建及其生物学意义

目的 对抗肿瘤药的天然耐药和化疗过程中产生的继发性耐药是肝癌化疗敏感性差的重要原因之一,为探讨体外逆转肝癌多药耐药(muhidrug resistance,MDR)的新方法,笔者建立了单因素人肝癌细胞多药耐药模型HepG2/mrp1,并研究其牛物学特性.方法 双酶切克隆质粒pGEMmrp1获得人全长多药耐药相关蛋白基因(mrp1),并将其插入哺乳动物表达载体pCI-neo的多克隆位点,构建重组载体,利用质脂体法将重组载体转入人肝癌细胞HepG2,建立单基因耐药细胞株HepG2/mrp1.观察细胞的生长规律;MTT法检测其多药耐药性;流式细胞仪检测细胞表面多药耐药相关蛋白(multidrug resistance-associated protein,MRP)的表达;RT-PCR检测MRP1 mRNA表达量.结果 与HepG2细胞相比较,HepG2/mrp1细胞的倍增时间延长30.86 h.该细胞对多种抗肿瘤药耐药,HepG2/mrp1对阿霉素和柔红霉素的耐药指数比亲本细胞增加了11.4倍和8倍,细胞表面MRPl的表达明显增加,mrp1 mRNA明显增加.结论 HepG2/mrp1细胞稳定高表达MRP1,具有多药耐药性,为进一步研究肝癌的多药耐药构建了一个技术平台.     

长链非编码RNA MALAT1在肝癌中表达及功能研究

目的:探讨长片段非编码RNA(lnc RNA)MALAT1在肝癌中的表达及其的功能。方法:用q RT-PCR方法检测80例肝癌患者手术切除的癌组织及其癌旁组织,以及不同肝癌细胞系(Hep G2、Hep3B、HCCLM3、Hu H7)与正常肝细胞系(L02)中MALAT1的表达。分别用MTT试验、划痕试验、流式细胞术检测肝癌细胞(Hep G2、Hu H7)转染MALAT1 si RNA后增殖、迁移、凋亡的变化。结果:80例配对标本中,72例(90%)肝癌组织MALAT1表达较其癌旁组织明显上调,MALAT1在不同肝癌细胞系中的表达水平均不同程度明显高于正常肝癌细胞(均P0.05);Hep G2、Hu H7转染MALAT1 si RNA后,增殖率均呈时间依赖性降低、划痕愈合能力均明显减弱(均P0.05),细胞凋亡率分别为17.0%、16.41%,而各自的对照组分别为8.89%、6.56%,差异有统计学意义(P0.05)。结论:MALAT1在肝癌中的表达上调,且可能与肝癌的恶性生物学行为密切相关,对其作用机制的进一步研究,有望为肝癌的治疗找到新的靶点。     

尾型同源盒转录因子2 shRNA慢病毒表达载体的构建及其转染对结肠癌细胞生长的影响

目的:构建尾型同源盒转录因子2(CDX2)shRNA慢病毒表达载体,并观察下调CDX2基因其对结肠癌细胞生长的影响。方法:根据CDX2 m RNA序列设计shRNA,并合成shRNA的互补序列,通过连接酶链接到GV248载体上,用测序方法鉴定阳性克隆后,将构建好的慢病毒表达载体与慢病毒包装载体用Lpofectamine 2000共转染293T细胞,产生慢病毒颗粒并用稀释法进行滴度测定。将CDX2 shRNA慢病毒表达载体转染人结肠癌细胞SW480、HT29后,分别用q RT-PCR和Western blot检测CDX2 m RNA及蛋白水平,CCK8实验及克隆形成实验检测细胞增殖能力。结果:DNA测序鉴定证实,CDX2 shRNA表达片段正确插入GV248载体中,包装后的病毒滴度为1×109TU/m L;SW480、HT29细胞转染CDX2-shRNA慢病毒表达载体后,CDX2 mRNA及蛋白表达水平均明显降低(均P0.05),但细胞的增殖与克隆形成能力无明显改变(均P0.05)。结论:成功构建shRNA慢病毒表达载体,其转染结肠癌细胞后能有效地抑制CDX2基因的表达;下调CDX2基因对人结肠癌细胞的增殖无明显影响。     

肝再生磷酸酶-1稳定转染肝癌细胞株的建立及其生物学功能

目的 构建肝再生磷酸酶-1(PRL-1)真核表达载体,建立稳定过表达PRL-1的肝细胞癌Huh7细胞株,研究PRL-1在Huh7细胞中的生物学功能.方法 应用反转录-聚合酶链反应(RT-PCR)技术从人肝癌组织总RNA中扩增PRL-1基因编码区域(CDS)全长序列,与双酶切的pMSCV-PIG质粒连接,经PCR及测序鉴定pMSCV-血细胞凝集素(HA)-PRL-1载体构建成功.用293T细胞包装病毒,并感染Huh7细胞,1 mg/L嘌呤霉素持续加压筛选2周后,荧光显微镜、流式细胞仪、实时荧光定量聚合酶链反应(FQ-PCR)及Western blot检测PRL-1在Huh7中的表达.PRL-1稳定转染细胞株构建成功后,用细胞计数试剂盒(CCK-8)法进行细胞增殖实验、平板克隆形成实验和Transwell侵袭实验研究PRL-1在Huh7细胞中的生物学功能.结果 测序结果显示克隆的PRL-1基因CDS序列完全正确,且正确插入到pMSCV-PIG载体中,荧光显微镜及流式细胞仪检测结果显示细胞稳定转染效率在90％以上,FQ-PCR结果显示PRL-1稳定转染组其mRNA表达是对照组的(4.4±1.5)倍(P＜0.05),Western blot结果显示PRL-1在Huh7细胞中过表达.CCK-8细胞增殖实验结果显示PRL-1促进Huh7细胞增殖(P＜0.01).PRL-1稳定转染细胞2周克隆形成率为(26.7±1.9)％,明显高于对照组[(7.3±0.8)％,P＜0.01].PRL-1稳定转染组较对照组侵袭细胞数量增多(P＜0.01).结论 PRL-1肝细胞癌Huh7稳定转染细胞株构建成功,PRL-1促进Huh7细胞增殖、克隆形成及侵袭.     

Tip30真核表达载体的构建及其在HepG2细胞中的表达

目的：探讨人Tip30全长基因的真核表达载体pAAV-TIP30的构建,并观察其转染肝癌细胞株HepG2后的表达。方法：以正常人肝组织mRNA为模板,用RT-PCR方法扩增Tip30,利用限制性内切酶BamH I和Xba I,将Tip30基因克隆到真核表达载体pAAV-MCS中,并经酶切和测序鉴定。重组质粒转染HepG2细胞,运用Western blot法检测Tip30蛋白表达。结果：RT-PCR方法正确地扩增出全长Tip30基因。限制性内切酶酶切和测序结果证实Tip30基因克隆完全正确。重组质粒转染肝癌细胞系HepG2后,Western blot证实Tip30蛋白表达增高。结论：成功构建了真核表达重组质粒pAAV-TIP30并转染HepG2细胞,为进一步研究Tip30基因对肝癌的影响及其机制打下了基础。     

靶向bcl-2基因StealthTM RNA干扰诱导肝癌细胞凋亡的作用

目的 应用RNA干扰技术,构建靶向bcl-2基因StealthTM RNA,转染入人肝癌细胞株,探讨RNA干扰诱导人肝癌细胞凋亡的机制.方法 确定并合成3对人肝癌bcl-2基因干扰序列;脂质体法转染入肝癌细胞株内;荧光显微镜下观察转染细胞并计算转染率;倒置显微镜下观察转染前后细胞形态学的改变;SP免疫细胞化学技术检测StealthTM RNA处理前后细胞bcl-2蛋白表达变化;流式细胞术检测StealthTM RNA干扰对癌细胞凋亡和周期的影响.结果 各组转染成功,荧光镜下显清晰的绿色荧光;各转染组转染率与时间有关,各组48 h的转染率最高(P＜0.01);转染组间StealthTM RNA Ⅰ组的转染效率最高(P＜0.01);倒置显微镜下观察见转染后见部分细胞边缘圆,折光度降低,细胞增殖减慢且易脱落;未转染组细胞呈上皮性贴壁生长,生长旺盛.免疫细胞化学显示,StealthTM RNA干扰后各转染组发现细胞的bcl-2表达减弱,与未转染组比较,差异有统计学意义(P＜0.01).流式细胞术结果示,各转染组细胞凋亡率明显升高,并出现凋亡峰,StealthTM RNA Ⅰ、Ⅱ、Ⅲ组的凋亡率分别为(27.87±4.51)%、(24.50±0.89)%和(26.03±0.57)%,与未转染组细胞凋亡率(3.20±1.71)%,差异有统计学意义(P＜0.01).各转染组细胞发生显著的细胞周期阻滞,表现为S期细胞明显减少,G0/G1细胞明显增多.结论 靶向bcl-2基因StealthTM RNA成功的转染人肝癌细胞中,bel-2蛋白表达受抑制,并明显的诱导癌细胞发生凋亡.     

Ku80基因RNAi逆转录病毒载体的构建及稳定转染人肾癌786-O细胞株的建立

目的 构建并鉴定逆转录病毒介导的Ku80基因RNA干扰表达体系,并建立稳定、高效、长久低表达Ku80的人肾癌786-O细胞株.方法 针对Ku80基因,设计并合成3对特异性RNA干扰靶序列,退火形成双链DNA,与BglⅡ和Hind Ⅲ双酶切后的pSUPERretro-puro载体连接,构建pSUPERretro-puro-siKu80干扰表达载体,并对重组载体进行测序鉴定.筛选出基因沉默效应最强的干扰序列后使用磷酸钙法共转染293FT细胞,产生的病毒颗粒随后感染786-O细胞,经嘌呤霉素筛选得到阳性克隆.用RT-PCR检测Ku80基因mRNA表达,Western blot测定转染后786-O细胞中Ku80蛋白的表达量,以鉴定稳定细胞株.结果 测序结果证实目的 片断正确插入pSUPERretro-puro表达载体中,成功构建了pSUPERretro-puro-siKu80干扰表达载体,稳定转染干扰表达载体的786-O细胞Ku80基因的表达显著降低.结论 成功构建了抑制Ku80基因表达的逆转录病毒载体,并获得Ku基因稳定干扰的人肾癌786-O细胞株,为下一步利用小干扰RNA技术研究肾癌的基因治疗奠定了基础.     

沉默RANK真核表达载体的构建及有效干扰序列的筛选

目的构建沉默小鼠RANK基因的真核表达载体pSuper-shRANK,筛选沉默RANK的最佳干扰序列。方法针对小鼠RANK基因设计并合成3对干扰序列,将其连接到真核表达载体pSuper上,酶切及测序鉴定正确后命名为pSuper-shRANK,后将其用脂质体瞬时转染小鼠骨髓巨噬细胞,用荧光显微镜观察转染情况,用Real-timePCR和Westernblot分析干扰效率。结果酶切分析与测序结果表明重组载体pSuper-shRANK构建成功,脂质体共转染后,Real-timePCR和Western blot分析结果显示shRANK-3干扰效果最好,干扰效率达88.7%,筛选出shRANK-3为最佳干扰序列。结论成功构建了沉默小鼠RANK基因的真核表达载体pSuper-shRANK;筛选出了沉默小鼠RANK的最佳干扰序列,为研究抑制该基因在破骨细胞分化及活化作用机制中奠定了基础。     

靶向性蛋白激酶B1和环氧合酶-2 shRNA腺病毒载体的构建和在人胃癌细胞的表达

Objective To construct a short hairpin RNA (shRNA) adenovirus vector targeting protein kinase BI (PKB1/Akt1) and cyclooxygenase-2 (COX-2) and observe their expression in human gastric carcinoma cell line SGC-7901. Methods Akt1 and COX-2 shRNA expression frames were sub-cloned to pGSadeno adenovirus vector by homologous recombination technology to construct pGSadeno-Aktl + COX-2 ( pGSadeno-A + C) vector. Furthermore after screening and amplification,recombinant ade-novirus vector was digested with Pacl and transfected into HEK293 cells. The replication adenovirus rAd5-A + C was packed and amplified in the HEK293 cells, and its titer was detected. After human SGC-7901 cells in vitro were transfected by rAd5-A + C,Akt1 and COX-2 mRNA and protein expression levels were detected by real-time PCR and Western blot respectively. Compared with rAdS-A + C,SGC-7901 and gen-eral rAd5-HK were selected as the negative controls. Results The recombinant adenovirus rAd5-A + C was constructed successfully and its titer reached 1.0 ×1010 pfu/ml. Aktl and COX-2 mRNA expression was downregulated significantly, and their ACt values ( 12.26±0.05 and 5.41±0.09 respectively ) were higher than rAd5-HK group (10.63±0.02 and 3.75 +0.08 respectively) and control group (10.57± 0.02 and 3.73±0.08 respectively) (P <0.01 ). There was no significant difference between rAd5-HK and control groups (P >0.05). Aktl and COX-2 protein expression was downregulated by 70.5% and 63.7% respectively ( P < 0.01 ) in rAd5-HK group as compared with control group ( P > 0.05 ). Conclu-sion The shRNA aclenovirus vector targeting Akt1 and COX-2 can specifically inhibit Akt1 and COX-2 expression,and this may be a new strategy in gastric carcinoma gene therapy targeting Akt1 and COX-2.     

靶向性蛋白激酶B1和环氧合酶-2 shRNA腺病毒载体的构建和在人胃癌细胞的表达

Objective To construct a short hairpin RNA (shRNA) adenovirus vector targeting protein kinase BI (PKB1/Akt1) and cyclooxygenase-2 (COX-2) and observe their expression in human gastric carcinoma cell line SGC-7901. Methods Akt1 and COX-2 shRNA expression frames were sub-cloned to pGSadeno adenovirus vector by homologous recombination technology to construct pGSadeno-Aktl + COX-2 ( pGSadeno-A + C) vector. Furthermore after screening and amplification,recombinant ade-novirus vector was digested with Pacl and transfected into HEK293 cells. The replication adenovirus rAd5-A + C was packed and amplified in the HEK293 cells, and its titer was detected. After human SGC-7901 cells in vitro were transfected by rAd5-A + C,Akt1 and COX-2 mRNA and protein expression levels were detected by real-time PCR and Western blot respectively. Compared with rAdS-A + C,SGC-7901 and gen-eral rAd5-HK were selected as the negative controls. Results The recombinant adenovirus rAd5-A + C was constructed successfully and its titer reached 1.0 ×1010 pfu/ml. Aktl and COX-2 mRNA expression was downregulated significantly, and their ACt values ( 12.26±0.05 and 5.41±0.09 respectively ) were higher than rAd5-HK group (10.63±0.02 and 3.75 +0.08 respectively) and control group (10.57± 0.02 and 3.73±0.08 respectively) (P <0.01 ). There was no significant difference between rAd5-HK and control groups (P >0.05). Aktl and COX-2 protein expression was downregulated by 70.5% and 63.7% respectively ( P < 0.01 ) in rAd5-HK group as compared with control group ( P > 0.05 ). Conclu-sion The shRNA aclenovirus vector targeting Akt1 and COX-2 can specifically inhibit Akt1 and COX-2 expression,and this may be a new strategy in gastric carcinoma gene therapy targeting Akt1 and COX-2.     

靶向性蛋白激酶B1和环氧合酶-2 shRNA腺病毒载体的构建和在人胃癌细胞的表达

Objective To construct a short hairpin RNA (shRNA) adenovirus vector targeting protein kinase BI (PKB1/Akt1) and cyclooxygenase-2 (COX-2) and observe their expression in human gastric carcinoma cell line SGC-7901. Methods Akt1 and COX-2 shRNA expression frames were sub-cloned to pGSadeno adenovirus vector by homologous recombination technology to construct pGSadeno-Aktl + COX-2 ( pGSadeno-A + C) vector. Furthermore after screening and amplification,recombinant ade-novirus vector was digested with Pacl and transfected into HEK293 cells. The replication adenovirus rAd5-A + C was packed and amplified in the HEK293 cells, and its titer was detected. After human SGC-7901 cells in vitro were transfected by rAd5-A + C,Akt1 and COX-2 mRNA and protein expression levels were detected by real-time PCR and Western blot respectively. Compared with rAdS-A + C,SGC-7901 and gen-eral rAd5-HK were selected as the negative controls. Results The recombinant adenovirus rAd5-A + C was constructed successfully and its titer reached 1.0 ×1010 pfu/ml. Aktl and COX-2 mRNA expression was downregulated significantly, and their ACt values ( 12.26±0.05 and 5.41±0.09 respectively ) were higher than rAd5-HK group (10.63±0.02 and 3.75 +0.08 respectively) and control group (10.57± 0.02 and 3.73±0.08 respectively) (P <0.01 ). There was no significant difference between rAd5-HK and control groups (P >0.05). Aktl and COX-2 protein expression was downregulated by 70.5% and 63.7% respectively ( P < 0.01 ) in rAd5-HK group as compared with control group ( P > 0.05 ). Conclu-sion The shRNA aclenovirus vector targeting Akt1 and COX-2 can specifically inhibit Akt1 and COX-2 expression,and this may be a new strategy in gastric carcinoma gene therapy targeting Akt1 and COX-2.     

靶向性蛋白激酶B1和环氧合酶-2 shRNA腺病毒载体的构建和在人胃癌细胞的表达

Objective To construct a short hairpin RNA (shRNA) adenovirus vector targeting protein kinase BI (PKB1/Akt1) and cyclooxygenase-2 (COX-2) and observe their expression in human gastric carcinoma cell line SGC-7901. Methods Akt1 and COX-2 shRNA expression frames were sub-cloned to pGSadeno adenovirus vector by homologous recombination technology to construct pGSadeno-Aktl + COX-2 ( pGSadeno-A + C) vector. Furthermore after screening and amplification,recombinant ade-novirus vector was digested with Pacl and transfected into HEK293 cells. The replication adenovirus rAd5-A + C was packed and amplified in the HEK293 cells, and its titer was detected. After human SGC-7901 cells in vitro were transfected by rAd5-A + C,Akt1 and COX-2 mRNA and protein expression levels were detected by real-time PCR and Western blot respectively. Compared with rAdS-A + C,SGC-7901 and gen-eral rAd5-HK were selected as the negative controls. Results The recombinant adenovirus rAd5-A + C was constructed successfully and its titer reached 1.0 ×1010 pfu/ml. Aktl and COX-2 mRNA expression was downregulated significantly, and their ACt values ( 12.26±0.05 and 5.41±0.09 respectively ) were higher than rAd5-HK group (10.63±0.02 and 3.75 +0.08 respectively) and control group (10.57± 0.02 and 3.73±0.08 respectively) (P <0.01 ). There was no significant difference between rAd5-HK and control groups (P >0.05). Aktl and COX-2 protein expression was downregulated by 70.5% and 63.7% respectively ( P < 0.01 ) in rAd5-HK group as compared with control group ( P > 0.05 ). Conclu-sion The shRNA aclenovirus vector targeting Akt1 and COX-2 can specifically inhibit Akt1 and COX-2 expression,and this may be a new strategy in gastric carcinoma gene therapy targeting Akt1 and COX-2.     

靶向性蛋白激酶B1和环氧合酶-2 shRNA腺病毒载体的构建和在人胃癌细胞的表达

Objective To construct a short hairpin RNA (shRNA) adenovirus vector targeting protein kinase BI (PKB1/Akt1) and cyclooxygenase-2 (COX-2) and observe their expression in human gastric carcinoma cell line SGC-7901. Methods Akt1 and COX-2 shRNA expression frames were sub-cloned to pGSadeno adenovirus vector by homologous recombination technology to construct pGSadeno-Aktl + COX-2 ( pGSadeno-A + C) vector. Furthermore after screening and amplification,recombinant ade-novirus vector was digested with Pacl and transfected into HEK293 cells. The replication adenovirus rAd5-A + C was packed and amplified in the HEK293 cells, and its titer was detected. After human SGC-7901 cells in vitro were transfected by rAd5-A + C,Akt1 and COX-2 mRNA and protein expression levels were detected by real-time PCR and Western blot respectively. Compared with rAdS-A + C,SGC-7901 and gen-eral rAd5-HK were selected as the negative controls. Results The recombinant adenovirus rAd5-A + C was constructed successfully and its titer reached 1.0 ×1010 pfu/ml. Aktl and COX-2 mRNA expression was downregulated significantly, and their ACt values ( 12.26±0.05 and 5.41±0.09 respectively ) were higher than rAd5-HK group (10.63±0.02 and 3.75 +0.08 respectively) and control group (10.57± 0.02 and 3.73±0.08 respectively) (P <0.01 ). There was no significant difference between rAd5-HK and control groups (P >0.05). Aktl and COX-2 protein expression was downregulated by 70.5% and 63.7% respectively ( P < 0.01 ) in rAd5-HK group as compared with control group ( P > 0.05 ). Conclu-sion The shRNA aclenovirus vector targeting Akt1 and COX-2 can specifically inhibit Akt1 and COX-2 expression,and this may be a new strategy in gastric carcinoma gene therapy targeting Akt1 and COX-2.     

靶向性蛋白激酶B1和环氧合酶-2 shRNA腺病毒载体的构建和在人胃癌细胞的表达

Objective To construct a short hairpin RNA (shRNA) adenovirus vector targeting protein kinase BI (PKB1/Akt1) and cyclooxygenase-2 (COX-2) and observe their expression in human gastric carcinoma cell line SGC-7901. Methods Akt1 and COX-2 shRNA expression frames were sub-cloned to pGSadeno adenovirus vector by homologous recombination technology to construct pGSadeno-Aktl + COX-2 ( pGSadeno-A + C) vector. Furthermore after screening and amplification,recombinant ade-novirus vector was digested with Pacl and transfected into HEK293 cells. The replication adenovirus rAd5-A + C was packed and amplified in the HEK293 cells, and its titer was detected. After human SGC-7901 cells in vitro were transfected by rAd5-A + C,Akt1 and COX-2 mRNA and protein expression levels were detected by real-time PCR and Western blot respectively. Compared with rAdS-A + C,SGC-7901 and gen-eral rAd5-HK were selected as the negative controls. Results The recombinant adenovirus rAd5-A + C was constructed successfully and its titer reached 1.0 ×1010 pfu/ml. Aktl and COX-2 mRNA expression was downregulated significantly, and their ACt values ( 12.26±0.05 and 5.41±0.09 respectively ) were higher than rAd5-HK group (10.63±0.02 and 3.75 +0.08 respectively) and control group (10.57± 0.02 and 3.73±0.08 respectively) (P <0.01 ). There was no significant difference between rAd5-HK and control groups (P >0.05). Aktl and COX-2 protein expression was downregulated by 70.5% and 63.7% respectively ( P < 0.01 ) in rAd5-HK group as compared with control group ( P > 0.05 ). Conclu-sion The shRNA aclenovirus vector targeting Akt1 and COX-2 can specifically inhibit Akt1 and COX-2 expression,and this may be a new strategy in gastric carcinoma gene therapy targeting Akt1 and COX-2.     

靶向性蛋白激酶B1和环氧合酶-2 shRNA腺病毒载体的构建和在人胃癌细胞的表达

Objective To construct a short hairpin RNA (shRNA) adenovirus vector targeting protein kinase BI (PKB1/Akt1) and cyclooxygenase-2 (COX-2) and observe their expression in human gastric carcinoma cell line SGC-7901. Methods Akt1 and COX-2 shRNA expression frames were sub-cloned to pGSadeno adenovirus vector by homologous recombination technology to construct pGSadeno-Aktl + COX-2 ( pGSadeno-A + C) vector. Furthermore after screening and amplification,recombinant ade-novirus vector was digested with Pacl and transfected into HEK293 cells. The replication adenovirus rAd5-A + C was packed and amplified in the HEK293 cells, and its titer was detected. After human SGC-7901 cells in vitro were transfected by rAd5-A + C,Akt1 and COX-2 mRNA and protein expression levels were detected by real-time PCR and Western blot respectively. Compared with rAdS-A + C,SGC-7901 and gen-eral rAd5-HK were selected as the negative controls. Results The recombinant adenovirus rAd5-A + C was constructed successfully and its titer reached 1.0 ×1010 pfu/ml. Aktl and COX-2 mRNA expression was downregulated significantly, and their ACt values ( 12.26±0.05 and 5.41±0.09 respectively ) were higher than rAd5-HK group (10.63±0.02 and 3.75 +0.08 respectively) and control group (10.57± 0.02 and 3.73±0.08 respectively) (P <0.01 ). There was no significant difference between rAd5-HK and control groups (P >0.05). Aktl and COX-2 protein expression was downregulated by 70.5% and 63.7% respectively ( P < 0.01 ) in rAd5-HK group as compared with control group ( P > 0.05 ). Conclu-sion The shRNA aclenovirus vector targeting Akt1 and COX-2 can specifically inhibit Akt1 and COX-2 expression,and this may be a new strategy in gastric carcinoma gene therapy targeting Akt1 and COX-2.     

靶向性蛋白激酶B1和环氧合酶-2 shRNA腺病毒载体的构建和在人胃癌细胞的表达

Objective To construct a short hairpin RNA (shRNA) adenovirus vector targeting protein kinase BI (PKB1/Akt1) and cyclooxygenase-2 (COX-2) and observe their expression in human gastric carcinoma cell line SGC-7901. Methods Akt1 and COX-2 shRNA expression frames were sub-cloned to pGSadeno adenovirus vector by homologous recombination technology to construct pGSadeno-Aktl + COX-2 ( pGSadeno-A + C) vector. Furthermore after screening and amplification,recombinant ade-novirus vector was digested with Pacl and transfected into HEK293 cells. The replication adenovirus rAd5-A + C was packed and amplified in the HEK293 cells, and its titer was detected. After human SGC-7901 cells in vitro were transfected by rAd5-A + C,Akt1 and COX-2 mRNA and protein expression levels were detected by real-time PCR and Western blot respectively. Compared with rAdS-A + C,SGC-7901 and gen-eral rAd5-HK were selected as the negative controls. Results The recombinant adenovirus rAd5-A + C was constructed successfully and its titer reached 1.0 ×1010 pfu/ml. Aktl and COX-2 mRNA expression was downregulated significantly, and their ACt values ( 12.26±0.05 and 5.41±0.09 respectively ) were higher than rAd5-HK group (10.63±0.02 and 3.75 +0.08 respectively) and control group (10.57± 0.02 and 3.73±0.08 respectively) (P <0.01 ). There was no significant difference between rAd5-HK and control groups (P >0.05). Aktl and COX-2 protein expression was downregulated by 70.5% and 63.7% respectively ( P < 0.01 ) in rAd5-HK group as compared with control group ( P > 0.05 ). Conclu-sion The shRNA aclenovirus vector targeting Akt1 and COX-2 can specifically inhibit Akt1 and COX-2 expression,and this may be a new strategy in gastric carcinoma gene therapy targeting Akt1 and COX-2.